Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized trial of PF-08634404 plus chemotherapy versus pembrolizumab plus chemotherapy in advanced non-small cell lung cancer
CTR20261302Phase 3Active
- Sponsor
- Pfizer
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of PF-08634404 in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Jun 2026; status: active.
02
Drugs
PF-08634404
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261302.